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SUMMARY
Mutations in the KCNQ2 gene encoding for voltage-gated potassium channel subunits
have been found in patients affected with early onset epilepsies with wide phenotypic
heterogeneity, ranging from benign familial neonatal seizures (BFNS) to epileptic
encephalopathy with cognitive impairment, drug resistance, and characteristic elec-
troencephalography (EEG) and neuroradiologic features. By contrast, only fewKCNQ3
mutations have been rarely described, mostly in patients with typical BFNS. We
report clinical, genetic, and functional data from a family in which early onset epilepsy
and neurocognitive deficits segregated with a novel mutation in KCNQ3 (c.989G>T;
p.R330L). Electrophysiological studies in mammalian cells revealed that incorporation
of KCNQ3 R330L mutant subunits impaired channel function, suggesting a pathoge-
netic role for suchmutation. The degree of functional impairment of channels incorpo-
rating KCNQ3 R330L subunits was larger than that of channels carrying another
KCNQ3mutation affecting the same codon but leading to a different amino acid substi-
tution (p.R330C), previously identified in two families with typical BFNS. These data
suggest that mutations in KCNQ3, similarly to KCNQ2, can be found in patients with
more severe phenotypes including intellectual disability, and that the degree of the
functional impairment caused by mutations at position 330 in KCNQ3may contribute
to clinical disease severity.
KEY WORDS: Benign familial neonatal seizures, KCNQ, Cognitive impairment, Volt-
age-gated potassium channels, Epilepsy, Mutagenesis, Genotype-phenotype correlations.
Mutations in the KCNQ2 gene encoding for neuronal
potassium channel subunits cause neonatal epilepsies with
wide phenotypic heterogeneity, ranging from benign famil-
ial neonatal seizures (BFNS) with normal cognition and
unremarkable neuroimaging,1,2 to early onset epileptic
encephalopathy with mental retardation, suppression-burst
electroencephalography (EEG), and distinct neuroradiolog-
ic features.3 On the other hand, mutations in KCNQ3,
encoding for channel subunits forming heteromeric
KCNQ2/KCNQ3 potassium channels underlying the M-cur-
rent4 have been only rarely described, mostly in families
affected with benign epilepsy with variable age of onset and
good outcome. More recently, however, a KCNQ3mutation
has been found in two siblings with neonatal seizures and
intellectual disability.5 Clinical, genetic, and functional
characterization of a family (Fig. 1A) in which epilepsy and
Accepted November 5, 2014; Early View publication December 19,
2014.
*Unit of Pharmacology, Department of Neuroscience, Reproductive
Science and Dentistry, University of Naples Federico II, Naples,
Italy; †Unit of Pediatric Neurology and Muscular Diseases, Department of
Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and
Child Health, University of Genoa, “G. Gaslini” Institute, Genova,
Italy; ‡Department of Medicine and Health Science, University of Molise,
Campobasso, Italy; §Unit of Child Neuropsychiatry, Department of
Sciences for Health Promotion and Mother and Child Care “G.
D’Alessandro,” University of Palermo, Palermo, Italy; ¶Laboratory of
Neurogenetics, Department of Neuroscience, “G. Gaslini” Institute, Genoa,
Italy; **Department of Pediatrics, Second University of Naples, Naples,
Italy; ††IRCCS “Oasi Maria SS” Troina (EN), Italy; and ‡‡Units of
Biophysics, National Research Council of Spain, University of the Basque
Country, Leioa, Spain
1These authors contributed equally to the manuscript; both serve as
corresponding authors.
Address correspondence to Maurizio Taglialatela, Department of Medi-
cine and Health Sciences, University of Molise, Via De Sanctis, 86100 –
Campobasso, Italy. E-mail: m.taglialatela@unimol.it
Wiley Periodicals, Inc.
© 2014 International League Against Epilepsy
e15
BRIEFCOMMUNICATION
neurocognitive deficits segregated with a novel mutation in
KCNQ3 is reported.
Methods
Standard protocol approvals and patient consent
The institutional review boards of the University of
Palermo and of the “G. Gaslini” Institute provided ethical
approval. All participants provided written informed con-
sent.
Cognitive evaluation
Cognitive assessment was performed using the
age-appropriate Wechsler Scale of Intelligence.
Genetic analysis
The probands (individuals III:1 and III:2) were screened
for KCNQ2 and KCNQ3 mutations by direct sequencing of
amplified genomic DNA. Variants were classified as muta-
tions according to previously described criteria.5
Mutagenesis and heterologous expression of KCNQ2 and
KCNQ3 subunits
Mutations were engineered by QuikChange mutagenesis
(Stratagene, Milan, Italy) in human KCNQ3 compementary
DNA (cDNA) (NM_004519.2) cloned into pcDNA3.1.6
Plasmids were transiently transfected in Chinese Hamster
Ovary (CHO) cells using Lipofectamine 2000 (Invitrogen,
Milan, Italy).
Whole-cell electrophysiology
Macroscopic current recordings from CHO cells and data
analysis were performed as described.6 In the experiments with
tetraethylammonium (TEA), currents were activated by 3-s
voltage ramps from 80 mV to +20 mV at 0.08-Hz
frequency. TEA blockade was expressed as the percentage of
peak current inhibition produced by a 2-min drug application.
Statistics
Data are expressed as the mean  standard error of the
mean (SEM). Statistically significant differences were eval-
uated with the Student’s t-test (p < 0.05) and indicated with
appropriate symbols.
Results
Case descriptions
Individual III:1
This 12-year-old boy was born at 38 weeks of gestation
after uneventful pregnancy and spontaneous delivery. Birth
weight was 2900 g, height 54 cm, and head circumference
A
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Figure 1.
Pedigree of the family and EEG of the
two affected siblings. (A) Pedigree of
the family. “+” = wild-type KCNQ3
allele; “” = mutant KCNQ3 allele;
“?” indicates DNA not available. (B)
Interictal sleep EEGs showing focal
sharp waves and sharp waves
complex over the right frontocentral
regions in patient III:1 (left) and
biphasic spike and spike wave
complexes over the left
frontotemporal areas in patient III:2
(right).
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35.5 cm. From day 2 to day 4 of life, the patient experienced
clusters of focal seizures characterized by staring and clonic
manifestations involving asymmetrically the four limbs,
and was treated with phenobarbital. Head control, sitting
without support, and walking were achieved at 4, 7 and
18 months, respectively. He spoke words at 12 months and
two-word phrases at 30 months. At 36 months of life,
6 months after phenobarbital withdrawal, the patient expe-
rienced four focal tonic–clonic seizures preceded by right
head deviation and staring, at awakening. Valproic acid was
started and the boy remained seizure-free up to the age of
10 years, when he manifested occasional episodes of right
or left hemiclonic seizures during sleep. At that time, his
EEG revealed sharp waves and sharp wave complex over
the right frontotemporal areas increased by drowsiness on
normal background activity (Fig. 1B, left). Neurologic
examination showed clumsiness without gross neurologic
deficits. At 11 years and 3 months, he showed mild intel-
lectual disability (ID) (full scale IQ 53, 99% confidence
interval [CI] 47–63; verbal IQ 47, 99% CI 41–61; perfor-
mance IQ 70, 99% CI 63–83). His academic skills remained
impaired and he received permanent educational support at
school. Brain magnetic resonance imaging (MRI) per-
formed at 8 years of age was unremarkable. The patient
remained seizure-free by increasing the daily dose of valp-
roic acid (30 mg/kg/day).
Individual III:2
This 9-year-old girl was born at term from unrelated parents
after an uneventful pregnancy and delivery. Her birth weight
was 2700 g. At day 2 of life she presented a cluster of focal
seizures characterized by staring and clonic movements
involving asymmetrically the four limbs, successfully treated
with phenobarbital. At age 4 months she experienced a cluster
of right hemiclonic seizures during sleep, treated with valpro-
ate. Head control, sitting without support, and walking were
achieved at 4, 8, and 24 months, respectively. The girl spoke
her first words at 3 years, and subsequent acquisition of devel-
opmental milestones was mildly slowed. At 4 years of age,
she began to have monthly right hemiclonic seizures during
sleep and isolated, brief dyscognitive seizures occurring
mainly at awakening. Brain MRI performed at 4 years of age
was unremarkable. Interictal EEG, performed at 6 years and
9 months of age, revealed normal background activity and
asynchronous biphasic spike and spike wave complexes
increasing during sleep, more evident over the left frontotem-
poral areas (Fig. 1 B, right); as was the case for individual
III:1, neonatal EEG for III:2 is not available. Neurologic exam-
ination showed mild dysmetria and ataxia, nystagmus, and fine
motor difficulties. The girl easily engaged in activities and
played with simple toys and exhibited oppositional behavior
and hyperactivity. She had severe language impairment with
phonetic-phonologic difficulties, poor vocabulary, and two-
word phrases. Cognitive assessment showed severe ID (full
scale IQ 38, 99% CI 37–50; verbal IQ 45, 99% CI 42–57;
performance IQ 40, 99% CI 37–53). At the last evaluation, her
academic skills remained impaired and she was receiving per-
manent educational support at school. She is seizure-free on
carbamazepine (20 mg/kg/day) and valproate (25 mg/kg/day).
Additional family members
The mother of the siblings (II:3), currently 42-year-olds,
with no history of neonatal seizures, experienced occasional
brief focal seizures with staring and right head and eye devi-
ation, sometimes followed by secondary generalization
from age 10 years and disappearing 2 years later without
treatment. Her intellectual assessment revealed a global IQ
at the lower level of the normal range (full scale IQ 71, ver-
bal IQ 65, performance IQ 85); her EEG is normal, and she
engages in a work activity and takes care of her family. The
father of two patients (II:2) is a 40 year old man with an
unremarkable personal clinical history; he engages in a
work activity, his EEG is normal, and the intellectual assess-
ment displays a global IQ level within the normal range (full
scale IQ 98, verbal IQ 82, and performance IQ 119). The
grandmother (I:4) is a 64-year-old woman who did not have
neonatal seizures but experienced rare motor seizures from
14 years of age; her intellectual assessment shows mild cog-
nitive impairment (full scale IQ 69, verbal IQ 68, perfor-
mance IQ 77). Individual II:4, the sister of II:3, currently
36-years-old, had neonatal-onset seizures remitting after
3 months; she also displayed moderate cognitive impair-
ment (full scale IQ 50, verbal IQ 48, performance IQ 63).
Additional family history is unremarkable, except for indi-
vidual II:1, who had focal recurrent motor and tonic–clonic
seizures beginning at age of 40 days following brain injury
and lasting until 34 years of age, when he died accidentally.
Genetic and functional studies
A c.989G>T mutation in KCNQ3, causing a leucine sub-
stitution of the highly conserved arginine residue at position
330 in the pore-forming region, immediately before the
sixth putative transmembrane domain S6 (Q3 R/L;
Fig. 2A), was found in III:1, III:2, II:3, and I:4, but not in
individual II:2; DNA from individual II:4 was not available.
NoKCNQ2mutation was detected in the probands. A differ-
ent KCNQ3 mutation at position 330 (R330C; Q3 R/C) has
been described in families showing typical BFNS features
including age of onset and remission of seizures, sensitivity
to AEDs, no recurrence of seizures after the neonatal period,
and normal neurocognitive development.7,8 Heterologously
expressed homomeric Q3 channels generated slowly acti-
vating voltage-dependent K+ currents; by contrast, cells
expressing Q3 R/L or R/C mutant subunits failed to generate
detectable currents (Fig. 2B). However, mutant subunits
could be partially rescued in heteromeric channels when
expressed with KCNQ2 (Q2) subunits (Q2:Q3mut cDNA
ratio 1:1) (Fig. 2E). Maximal current size at 0 mV was
larger in Q2 + Q3 R/C than in Q2 + Q3 R/L heteromeric
channels (Fig. 2E). Heteromerization of Q2 with Q3
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subunits is known to reduce current sensitivity to TEA
blockade;4 in fact, the percent of currents blocked by 3 mM
TEA was 87.8  3, 8  2, and 48.8  4.2 in Q2, Q3, and
Q2 + Q3 channels, respectively (n = 6–13; p < 0.05). Cur-
rent blockade by 3 mM TEA (in %) was 71.2  2.1 and
64.6  2 in Q2 + Q3 R/L and Q2 + Q3 R/C channels,
respectively (n = 6–13); these values were higher than
those of Q2 + Q3 channels, and different from each other
(p < 0.05). Altogether, these results suggest that Q3 R/L su-
bunits produce greater functional deficits than R/C subunits
in heteromeric channels with Q2.
To mimic the genetic condition of the affected patients
who carry a single Q3 mutant allele, CHO cells were also
transfected with Q2 + Q3 + Q3 R/L or Q2 + Q3 + Q3 R/
C cDNAs at a 1:0.5:0.5 ratio. When compared to heteromer-
ic Q2 + Q3 channels, current density from Q2 + Q3 + Q3
R/L-transfected cells was significantly reduced; by contrast,
we were unable to detect significant changes in macroscopic
current density between cells transfected with
Q2 + Q3 + Q3 R/C and Q2 + Q3 (Fig. 2E). No changes in
gating steady-state properties could be detected among
Q2 + Q3, Q2 + Q3 + Q3 R/L, and Q2 + Q3 + Q3 R/C
channels (Fig. 2D); the V½ (in mV) and k (in mV/e-fold)
values were 29.5  1.1, 27  1.2, 30.9  1.6, and
13.3  0.5, 12.5  0.6, 11.8  0.8, respectively (p >
0.05; n = 10–15 cells per group). Activation kinetics were
also unaffected, as the activation s at 0 mV (in msec) were
137  18, 171  29, and 136  23, respectively, for
Q2 + Q3, Q2 + Q3 + Q3 R/L, and Q2 + Q3 + Q3 R/C
channels (p > 0.05; n = 10–15 cells per group).
Discussion
We report a family with two affected siblings display-
ing an uncommon clinical course characterized by recur-
rent seizures beyond the typical age window of BFNS
A B
C
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Figure 2.
Schematic representation of a KCNQ subunit topology and functional analysis of KCNQ3mutations at position 330. (A) Schematic draw-
ing of a single KCNQ subunit. Transmembrane segments are indicated as S1-S6. The star indicates the R330 position. (B,C) Macroscopic
currents from the indicated homomeric (B) or heteromeric (C) channels. In (B) current scale 20 pA, time scale 100 msec; in (C) current
scale 200 pA, time scale 100 msec. (D) Conductance/voltage curves. Continuous lines are Boltzmann fits.5 (E) Average current densities
from the indicated channels. *, p<0.05 versus Q2+Q3 (1:1); **, p<0.05 versus Q2+Q3 (1:0.5); #, p<0.05 versus Q2+Q3 R/L. Note the sta-
tistically significant difference in current density between Q3 R/C- and Q3 R/L-containing heteromers. Number in parenthesis indicate
the transfected cDNA ratios (Q2:Q3:Q3mut). n = 13–24 cells per group recorded in at least three separate experimental sessions.
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associated with ID and segregating with a novel KCNQ3
mutation.
The identification of a KCNQ3 mutation associated with
more severe phenotypes represents a rather novel finding
and parallels the emerging data on KCNQ2.3,9 To date, only
nine missense KCNQ3 mutations have been reported in
families with early onset epilepsies; seven in BFNS,5,7,8,10–14
and two in patients with seizure occurrence in the infantile
age.15,16 In most families with KCNQ3 mutations, affected
members showed a benign disease course including age of
onset and remission of seizures, sensitivity to AEDs, no
recurrence of seizures after the neonatal-infantile period,
and normal neurocognitive development. By contrast, in the
family described by Soldovieri et al.,5 febrile seizures
beyond the neonatal period and mild to moderate intellec-
tual deficiency occurred in two patients; moreover, an asso-
ciation between infantile seizures and centrotemporal
spikes (CTS) on EEG was described by Fusco et al.16 The
presently found mutation (p.R330L) affects the same codon
previously reported to be mutated in two BFNS families
from different ethnic backgrounds (p.R330C),7,8 and in an
additional BFNS family (p.R330H).14 The present data
reveal that both R330L and R330C Q3 mutations abolished
channel function in homomeric configuration, but could be
partially rescued in heteromeric channels with Q2 or Q2/Q3
subunits. The degree of functional impairment was signifi-
cantly greater for R330L than for R330C mutant Q3 subun-
its, suggesting that the unusual clinical course displayed by
the two probands described in the present study may be
caused by the underlying specific KCNQ3 mutation, as
described previously for KCNQ2.6,17 Although several
mechanisms may account for the mutation-induced reduc-
tion in maximal current, the fact that TEA sensitivity is
affected by both R330 mutations investigated seems to sug-
gest an impaired incorporation of mutant subunits into func-
tional heteromeric channels. Given the variability in the
expression system (Xenopus oocytes vs. mammalian cells)
and in the experimental setup (not all mutations have been
studied in the pathophysiologically relevant 1:0.5:0.5 ratio
among Q2:Q3:Q3mut subunits), it is difficult to compare
the present functional data with those previously obtained
with other KCNQ3mutations investigated by electrophysio-
logical experiments. Nevertheless, among Q3 mutations
associated with mostly a benign clinical course, although
E299K, D305G, and G310V mutations caused a 20–40%
reduction in the maximal current of heteromeric Q2/Q3
channels when expressed in Xenopus oocytes,12,18,19 the
W309R mutation reduced by >60% channel currents in
HEK293 cells, suggesting a dominant-negative effect.20,21
In our study, a current decrease by about 30% in R330L
mutant channels was found, whereas the I317T mutation
described in two siblings with moderate psychomotor delay
reduced heteromeric currents by >60%.5 Thus, definitive
conclusions about potential genotype–phenotype correla-
tions cannot be drawn at this stage.
Notably, our patients showed the typical centrotemporal
EEG abnormalities; this age-dependent genetic trait has been
previously described in patients with favorable clinical course
carrying mutations in KCNQ222–24 or KCNQ3.16 As the CTS
trait is also linked with a wide spectrum of nonepileptic condi-
tions ranging from mild selective performance deficits to
complex ID, we hypothesize, as previously suggested,25 that
the coincidence of more traits, either of which has little or no
clinical significance alone, may produce substantial clinical
effects. In the family herein investigated, the lack of neonatal
seizures, considered to be the hallmark of KCNQ3 pathology,
in some individuals may be due to the incomplete penetrance
reported in up 10–15% of individuals with BFNS.26 Although
the possible presence of cosegregating genetic factor(s)
responsible for the ID and focal seizures cannot be fully
excluded in this family at this stage, the variable phenotype
observed may be caused by additional genetic, epigenetic, or
environmental factors modulating the expressivity of the Q3
R330L mutation; their identification might improve prognos-
tic predictions and genetic counseling.
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